Latest Treatments In Osteoporosis: Innovations That Are Bringing Maximum Impact
According to research by Ohio State University College of Pharmacy, one in three women and one in five men will experience osteoporotic symptoms over the age of 50 years old. There are currently 200 million people living with osteoporosis, a condition described as an increase in bone fragility or “gradual thinning of the bones” that is normally seen as you age, but is accelerated with those with this bone disease. Although there is currently no available treatment for osteoporosis, new developments in research have revealed breakthroughs in therapeutic methods to approach osteoporosis and other bone diseases.
A new type of bone cell discovered
The research team at Garvan Institute of Medical Research has also discovered a new type of bone cell that may be targeted for the treatment of bone diseases. The newly discovered cells, osteo morphs, were observed to be formed in the process of bone resorption, where specialized cells known as osteoclasts break down old bone and repair it again. Under an intravital imaging technology, researchers observed that osteoclasts break down into smaller cells (osteo morphs) and join together again in the process of bone resorption. A disturbance in this balance can lead to multiple bone diseases such as osteoporosis, which can be prevented with the use of osteoanabolic treatments. In fact, anabolic therapy has been found to slow osteoporosis, according to the National Library of Medicine.
“Completely New Process”
“The process was completely new to us,” said Dr. McDonald, author and leader of the research team at Garvan. They hypothesized that the reason the osteoclasts divide further into osteo morphs and join together again is in order to increase the lifespan of the bone tissue. These cells are also found in the blood and bone marrow, which suggests that they are widely distributed to all parts of the skeleton. It is also likely a reservoir for cells that specialize in repair to be released when needed.